Clinical Trial Update: A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01) [Phase 3]

View source ↗

Summary

A Phase 3 study (BEHOLD-Ovarian01) is investigating GSK5733584 versus chemotherapy in platinum-resistant ovarian cancer; the trial is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• GSK5733584

Snippet

Sponsor: GlaxoSmithKline | Conditions: Ovarian Neoplasms | Phase 3 | Status: NOT_YET_RECRUITING